Patent US20050149112A1 successfully refreshed from Google Patents.
US5792453A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Gene transfer-mediated angiogenesis therapy
Assignee: University of California
•
Filing: 1995-06-07
•
Granted: 1998-08-11
•
Expires: 2015-06-07
Abstract
Abstract The transgene-inserted replication-deficit adenovirus vector is effectively used in in vivo gene therapy for peripheral vascular disease and heart disease, including myocardial ischemia, by a single intra-femoral artery or intracoronary injection directly conducted deeply in the lumen of the one or both femoral or coronary arteries (or graft vessels) in an amount sufficient for transfecting cells in a desired region.
Inventors
- 👤 H. Kirk Hammond
- 👤 Frank J. Giordano
- 👤 Wolfgang H. Dillmann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:17
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1858; A61K38/1866; A61P; A61P9/00; A61P9/10; A61P9/14; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/50; A61K48/00; C12N2710/00; C12N2710/00011; C12N2710/10011; C12N2710/10311; C12N2710/10341; C12N2710/10343; C12N2830/00; C12N2830/008
Claims Analysis
Total Claims: 44
Claim 1
Independent Claim
59 words
A method for stimulating coronary collateral vessel development in a patient, comprising delivering a replication-deficient adenovirus vector to the myocardium of the patient by intracoronary injection directly into one or both coronary arteries, said vector comprising a transgene coding for an angiogenic protein or peptide, and which expresses the transgene in the myocardium, thereby promoting coronary collateral vessel development.
Claim 2
Independent Claim
59 words
A method for stimulating coronary collateral vessel development in a patient, comprising delivering a replication-deficient adenovirus vector to the myocardium of the patient by intracoronary injection directly into one or both coronary arteries, said vector comprising a transgene coding for an angiogenic protein or peptide, and which expresses the transgene in the myocardium, thereby promoting coronary collateral vessel development.
Claim 3
Dependent Claim
14 words
The method of claim 1, wherein a single injection of said vector is delivered.
Claim 4
Dependent Claim
21 words
The method of claim 1, wherein about 10 7 to about 10 13 adenovirus vector particles are delivered in the injection.
Claim 5
Dependent Claim
21 words
The method of claim 1, wherein about 10 9 to about 10 12 adenovirus vector particles are delivered in the injection.
Claim 6
Dependent Claim
17 words
The method of claim 1, wherein about 10 11 adenovirus vector particles are delivered in the injection.
Claim 7
Dependent Claim
21 words
The method according to claim 1, wherein said transgene is driven by a CMV promoter which is contained in the vector.
Claim 8
Dependent Claim
22 words
The method according to claim 1, wherein said transgene is driven by a ventricular myocyte-specific promoter which is contained in the vector.
Claim 9
Dependent Claim
19 words
The method according to claim 7, wherein said ventricular myocyte-specific promoter has the sequences of ventricular myosin light chain-2.
Claim 10
Dependent Claim
19 words
The method according to claim 7, wherein said ventricular myocyte-specific promoter has the sequences of myosin heavy chain promoter.
Claim 11
Dependent Claim
16 words
The method of claim 1, wherein said angiogenic protein or peptide is a fibroblast growth factor.
Claim 12
Dependent Claim
14 words
The method of claim 10, wherein said angiogenic protein is fibroblast growth factor 5.
Claim 13
Dependent Claim
14 words
The method of claim 10, wherein said angiogenic protein is acidic fibroblast growth factor.
Claim 14
Dependent Claim
14 words
The method of claim 10, wherein said angiogenic protein is basic fibroblast growth factor.
Claim 15
Dependent Claim
14 words
The method of claim 1, wherein said angiogenic protein is vascular endothelial growth factor.
Claim 16
Dependent Claim
26 words
The method of claim 1, wherein said intracoronary injection is conducted at least about 1 cm into the lumens of the left and right coronary arteries.
Claim 17
Dependent Claim
36 words
The method of claim 1, wherein said intracoronary injection is conducted at least about 1 cm into the lumens of a sapheous vein graft and/or an internal mammary artery graft in addition to a coronary artery.
Claim 18
Dependent Claim
32 words
The method of claim 1, wherein said transgene is operably linked to a tissue specific promoter which is contained in the vector whereby expression of said transgene is controlled by said promoter.
Claim 19
Dependent Claim
11 words
The method of claim 1, wherein said patient has myocardial ischemia.
Claim 20
Independent Claim
63 words
A method for stimulating vessel development in a patient having peripheral-deficient vascular disease, comprising delivering a replication-deficient adenovirus vector to the peripheral vascular system of the patient by intra-femoral artery injection directly into one or both femoral arteries, said vector comprising a transgene coding for an angiogenic protein or peptide, and the transgene in the peripheral vascular system, thereby promoting peripheral vascular development.
Claim 21
Independent Claim
63 words
A method for stimulating vessel development in a patient having peripheral-deficient vascular disease, comprising delivering a replication-deficient adenovirus vector to the peripheral vascular system of the patient by intra-femoral artery injection directly into one or both femoral arteries, said vector comprising a transgene coding for an angiogenic protein or peptide, and the transgene in the peripheral vascular system, thereby promoting peripheral vascular development.
Claim 22
Dependent Claim
14 words
The method of claim 19, wherein a single injection of said vector is delivered.
Claim 23
Dependent Claim
21 words
The method of claim 19, wherein about 10 9 to about 10 13 adenovirus vector particles are delivered in the injection.
Claim 24
Dependent Claim
21 words
The method of claim 19, wherein about 10 9 to about 10 12 adenovirus vector particles are delivered in the injection.
Claim 25
Dependent Claim
17 words
The method of claim 19, wherein about 10 11 adenovirus vector particles are delivered in the injection.
Claim 26
Dependent Claim
24 words
The method according to claim 33, wherein said angiogenic protein or peptide is selected from the group consisting of aFGF, bFGF, FGF-5, and VEGF.
Claim 27
Independent Claim
48 words
A method for treating heart myocardial ischemia, comprising delivering a replication-deficient adenovirus vector to the myocardium of a patient by intracoronary injection, said vector comprising a transgene coding for an angiogenic protein or peptide, and which expresses the transgene in the myocardium, thereby promoting coronary collateral vessel development.
Claim 28
Independent Claim
48 words
A method for treating heart myocardial ischemia, comprising delivering a replication-deficient adenovirus vector to the myocardium of a patient by intracoronary injection, said vector comprising a transgene coding for an angiogenic protein or peptide, and which expresses the transgene in the myocardium, thereby promoting coronary collateral vessel development.
Claim 29
Dependent Claim
17 words
The method of claim 25, wherein said intracoronary injection is directed to one or both coronary arteries.
Claim 30
Dependent Claim
16 words
The method of claim 25, wherein said intracoronary injection is directed to the left coronary artery.
Claim 31
Dependent Claim
23 words
The method of claim 26, wherein said intracoronary injection is conducted at least about 1 cm into the lumens of both coronary arteries.
Claim 32
Dependent Claim
39 words
The method of claim 28, wherein said intracoronary injection is conducted at least about 1 cm into the lumens of a saphenous vein graft or an internal mammary artery graft in addition to the left or right coronary arteries.
Claim 33
Dependent Claim
37 words
The method of claim 29, wherein said intracoronary injection is conducted at least about 1 cm into the lumens of a saphenous vein graft or an internal mammary artery graft in addition to the left coronary artery.
Claim 34
Dependent Claim
37 words
The method of claim 39, wherein said intracoronary injection is conducted at least about 1 cm into the lumens of a saphenous vein graft or an internal mammary artery graft in addition to the right coronary artery.
Claim 35
Dependent Claim
16 words
The method of claim 25, wherein said angiogenic protein or peptide is a fibroblast growth factor.
Claim 36
Dependent Claim
14 words
The method of claim 25, wherein said angiogenic protein is fibroblast growth factor 5.
Claim 37
Dependent Claim
16 words
The method of claim 25, wherein said intracoronary injection is directed to the right coronary artery.
Claim 38
Dependent Claim
24 words
The method of claim 25, wherein said intracoronary injection is conducted at least about 1 cm into the lumen of the left coronary artery.
Claim 39
Dependent Claim
24 words
The method of claim 25, wherein said intracoronary injection is conducted at least about 1 cm into the lumen of the right coronary artery.
Claim 40
Independent Claim
20 words
The method of any one of claims 25, wherein said angiogenic protein or peptide is a vascular endothelial growth factor.
Claim 41
Independent Claim
17 words
The method of claims 1 or 25, wherein expression of said transgene is limited to the heart.
Claim 42
Dependent Claim
16 words
The method of claim 38, wherein expression of said transgene is limited to the cardiac myocytes.
Claim 43
Dependent Claim
17 words
The method of claim 39, wherein expression of said transgene is limited to the ventricular cardiac myocytes.
Claim 44
Independent Claim
32 words
The method of claims 10 or 32, wherein said fibroblast growth factor is selected from the group consisting of acidic fibroblast growth factor, basic fibroblast growth factor, and fibroblast growth factor 5.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-08-10 | 2002-02-09 | 2002-08-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-08-10 | 2006-02-09 | 2006-08-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-08-10 | 2010-02-09 | 2010-08-11 | $7700.00 | Window Closed / Lapsed |